Article in Viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
12 authors.
Li MaTulane National Primate Research Center, Tulane University School of Medicine, 18703 Three Rivers Road, Covington, LA 70433, USA.ORCID 0009-0003-6766-9008
Yoshiaki NishimuraLaboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Xueling WuDepartment of Medicine, Infectious Diseases, Boston University School of Medicine, Boston Medical Center, 650 Albany Street, Boston, MA 02118, USA.ORCID 0000-0002-9752-3734
Olivia DonauLaboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0002-8184-7849
Eunice VincentTulane National Primate Research Center, Tulane University School of Medicine, 18703 Three Rivers Road, Covington, LA 70433, USA.
Hong LuDepartment of Medicine, Infectious Diseases, Boston University School of Medicine, Boston Medical Center, 650 Albany Street, Boston, MA 02118, USA.
Robert V BlairTulane National Primate Research Center, Tulane University School of Medicine, 18703 Three Rivers Road, Covington, LA 70433, USA.ORCID 0000-0001-9616-9414
Lara A Doyle-MeyersTulane National Primate Research Center, Tulane University School of Medicine, 18703 Three Rivers Road, Covington, LA 70433, USA.
Malcolm MartinLaboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0003-1232-2966
Ronald S VeazeyTulane National Primate Research Center, Tulane University School of Medicine, 18703 Three Rivers Road, Covington, LA 70433, USA.ORCID 0000-0002-6298-2391
Huanbin XuTulane National Primate Research Center, Tulane University School of Medicine, 18703 Three Rivers Road, Covington, LA 70433, USA.ORCID 0000-0003-1742-0979
Xiaolei WangTulane National Primate Research Center, Tulane University School of Medicine, 18703 Three Rivers Road, Covington, LA 70433, USA.ORCID 0000-0003-4081-8985
Funding
Tulane NPRC SPF Sheltered Outdoor Enclosure ExpansionP51OD011104 · OD · TULANE UNIVERSITY OF LOUISIANA · PI L Lee HAMM · 2012 to 2026
$142.4M
Viral Testing CoreU42OD024282 · OD · TULANE UNIVERSITY OF LOUISIANA · PI KASI E RUSSELL-LODRIGUE · 2017 to 2026
$25.7M
Viral Testing Core - Maintenance of an SPF Macaque Breeding Colony for AIDS ResearchU42OD010568 · OD · TULANE UNIVERSITY OF LOUISIANA · PI KASI E RUSSELL-LODRIGUE · 2013 to 2026
$21.7M
Impact of tuberculosis on the development and function of the immune system in SIV-infected infantsR01HD099857 · NICHD · TULANE UNIVERSITY OF LOUISIANA · PI KAUSHAL, DEEPAK, WANG, XIAOLEI · 2019 to 2023
$6.9M
Resource CoreP40OD028116 · OD · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Diogo Magnani · 2020 to 2026
$5.9M
Mtb and HIV/SIV antigen peptide signatures as blood biomarkers to detect early infection to active disease in young children and NHPR01HD103511 · NICHD · TULANE UNIVERSITY OF LOUISIANA · PI LYON, CHRISTOPHER J · 2021 to 2025
$3.7M
Early prevention interventions towards ART-free pediatric HIV remissionR01MH133474 · NIMH · TULANE UNIVERSITY OF LOUISIANA · PI Ronald S. Veazey · 2023 to 2026
$3.0M
High Throughput Multicolor Flow Cytometer Cell AnalyzerS10OD026800 · OD · TULANE UNIVERSITY OF LOUISIANA · PI KAUR, AMITINDER · 2019 to 2019
$594k
national Institute of Child Health and Human Development HD099857National Institute of Child Health and Human Development HD103511NICHD NIH HHS R01 HD099857NICHD NIH HHS R01 HD103511NIH HHS P40 OD028116NIH HHS P51 OD011104NIH HHS S10 OD026800NIH HHS U42 OD010568NIH HHS U42 OD024282NIMH NIH HHS R01 MH133474ODCDC CDC HHS P40 OD028116ODCDC CDC HHS P51 OD011104ODCDC CDC HHS U42 OD010568ODCDC CDC HHS U42 OD024282
6 · The paper itself
Abstract
Infants born to HIV-positive mothers remain at significant risk of HIV acquisition despite maternal adherence to antiretroviral therapy, cesarean delivery, and formula feeding. Our previous study reported that initiating early antiretroviral treatment at three days post-SIV infection resulted in approximately eighty percent of pediatric virologic remission. In this study, we investigated treatment outcomes in postnatally SHIV-exposed infant macaques when early intervention was delayed by two days, as well as the mechanisms underlying virologic control. The results showed that, although initiating treatment at five days post-exposure effectively suppressed viral replication, only one of the three infant macaques achieved a sustained state of virologic remission following analytical treatment interruption. Notably, this virus-controlled infant lacked detectable virus-specific immunity, including neutralizing antibodies, cytotoxic T cell responses, and antibody-dependent cellular cytotoxicity. These findings highlight the critical importance of early treatment initiation as a key determinant of virologic control in HIV-exposed, infected infants. This study provides valuable insights for guiding early pediatric HIV intervention strategies in clinical settings.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Impact of Delayed Early Antiretroviral Therapy Initiation on Treatment Outcomes in Infant Macaques Exposed to SHIVAD8. · full record | OpenQuestion